



Access through your institution

 Outline  Get Access  Share  Export



## Ophthalmology Glaucoma

Volume 1, Issue 1, July–August 2018, Pages 75-81

Original Article

# Outcomes of Kahook Dual Blade Goniotomy with and without Phacoemulsification Cataract Extraction

Presented at: the American Glaucoma Society Annual Meeting, New York, NY, March 2018.

Erin G. Sieck MD<sup>1</sup>, Rebecca S. Epstein MD<sup>1</sup>, Jeffrey B. Kennedy MD<sup>1</sup>, Jeffrey R. SooHoo MD<sup>1</sup>, Mina B. Pantcheva MD<sup>1</sup>, Jennifer L. Patnaik PhD<sup>1</sup>, Brandie D. Wagner PhD<sup>1,2</sup>, Anne M. Lynch MD<sup>1</sup>, Malik Y. Kahook MD<sup>1</sup>, Leonard K. Seibold MD<sup>1</sup>  

[Show more](#) 

<https://doi.org/10.1016/j.ogla.2018.06.006>

[Get rights and content](#)

### Purpose

To determine the effectiveness and safety of Kahook Dual Blade (KDB) goniotomy in reducing [intraocular pressure](#) (IOP) and medication need in glaucoma patients when combined with [phacoemulsification](#) or as a standalone procedure.

### Design

Retrospective study.

### Participants

A total of 197 eyes from 143 patients were reviewed.

Thirty-two eyes underwent KDB goniotomy alone and 165 eyes underwent KDB goniotomy combined with phacoemulsification [cataract surgery](#) (phaco-KDB).

## Main Outcome Measures

Surgical success, defined as IOP reduction of at least 20% from baseline at 12 months, and/or reduction of at least 1 [glaucoma medication](#).

## Results

At 12 months, the success rate was 71.8% for the phaco-KDB group and 68.8% for the KDB-alone group. In the phaco-KDB group at 12 months ( $n = 124$ ), mean IOP was significantly reduced from 16.7 (standard error [SE] 0.4) mmHg on 1.9 (SE 0.1) medications to 13.8 (SE 0.4) mmHg on 1.5 (SE 0.1) medications. In the KDB-alone group at 12 months ( $n = 16$ ), mean IOP was significantly reduced from 20.4 (SE 1.3) mmHg on 3.1 (SE 0.2) medications to 14.1 (SE 0.9) mmHg on 2.3 (SE 0.4) medications. The most common complications were transient [hyphema](#) (17.3% at day 1) and IOP spike  $>10$  mmHg from baseline at 1 week (10.2%). LogMAR [visual acuity](#) at 12 months was unchanged from baseline in the KDB-alone group (0.218 [SE 0.07] and 0.306 [SE 0.09], respectively,  $P = 0.244$ ) and significantly improved in the phaco-KDB group (0.184 [SE 0.02] and 0.340 [SE 0.03],  $P < 0.001$ ).

## Conclusions

Goniotomy with the KDB has a favorable safety profile and is an effective procedure at reducing IOP and medication burden as a standalone procedure or combined with phacoemulsification.

[<](#) Previous

Next [>](#)

## Abbreviations and Acronyms

EVP, episcleral venous pressure; IOP, intraocular pressure; KDB, Kahook Dual Blade; POAG, primary open-angle glaucoma; SE, standard error; TM, trabecular meshwork

---

[Recommended articles](#)

Citing articles (0)

Financial Disclosure(s): The author(s) have made the following disclosure(s): E.G.S.: Consultant New World Medical.

M.Y.K.: Patent Kahook Dual Blade, which is licensed by New World Medical. The University of Colorado receives

HUMAN SUBJECTS: Human subjects were included in this study. The Colorado Multiple Institutional Review Board approved this study. The study conformed to the tenets of the Declaration of Helsinki. Patients did not provide consent as this was a retrospective chart review.

No animal subjects were used in this study.

Author Contributions:

Conception and design: Sieck, Epstein, Kennedy, Patnaik, Wagner, Lynch, Kahook, Seibold

Data collection: Sieck, Epstein, Kennedy, SooHoo, Pantcheva, Seibold

Analysis and interpretation: Sieck, Epstein, Kennedy, SooHoo, Pantcheva, Patnaik, Wagner, Lynch, Kahook, Seibold

Obtained funding: N/A

Overall responsibility: Sieck, Epstein, Kennedy, SooHoo, Pantcheva, Patnaik, Wagner, Lynch, Kahook, Seibold

[View full text](#)

© 2018 by the American Academy of Ophthalmology



[About ScienceDirect](#)

[Remote access](#)

[Shopping cart](#)

[Advertise](#)

[Contact and support](#)

[Terms and conditions](#)

[Privacy policy](#)

We use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the [use of cookies](#).

Copyright © 2020 Elsevier B.V. or its licensors or contributors. ScienceDirect® is a registered trademark of Elsevier B.V.

ScienceDirect® is a registered trademark of Elsevier B.V.

